KLK3 and pachyonychia congenita: There are a number of useful metrics for assessing response to many systemic therapies in patients with advanced PC, such as PSA kinetics, PSA nadir, PSA progression, PSA velocity, PSA doubling time, and time to PSA nadir (TTPN) (11–13).